Navigation Links
Dr. Titus Wong to Speak at International Photodynamic Association World Congress in Seoul

Vancouver, British Columbia (PRWEB) May 27, 2013

Ondine Biomedical Inc. announces that Dr. Titus Wong of the Vancouver General Hospital, will be speaking at the World Congress of the International Photodynamic Association (IPA) on May 28th through May 31st, 2013. Dr. Wong will be describing the protocols and benefits of Photodisinfection. Dr. Wong and his team were recently awarded the inaugural John Conly Innovation award at the 2012 AMMI-CACMID conference, recognizing a novel and creative strategy to improve patient safety and public health in Canada.

With growing worldwide recognition, MRSAid™ Photodisinfection System has become one of the most valuable technologies available in preventing surgery-related infections. Photodisinfection is a broad spectrum antimicrobial topical therapy that has been proven for decades to instantly and safely eliminate harmful pathogens such as antibiotic resistant superbugs. Vancouver General Hospital's use of MRSAid's innovative universal pre-surgical protocol resulted in a 39% reduction in surgical site infections and $1.9 million in cost savings.

The IPA World Congress is a biannual conference highlighting the advances in scientific and clinical research around the world. This year's Congress is being held May 28th to May 31st, 2013 at the Ritz-Carlton Hotel, Seoul, Korea. Global leaders in the field of PDT and their work will be represented during this event. Clinicians, scientists, researchers, hospital administrators, students are welcome to participate at this year's conference.

About International Photodynamic Association

The IPA was founded in 1986 and its membership consists of the most prominent international clinicians and scientists involved in performing and researching photodynamic therapy (PDT) and photodiagnosis (PD). The purpose of the IPA is to promote the study of diagnosis and treatment using light and photosensitisers, to disseminate such information to the members of the IPA, the medical community and to the general public. The IPA organises an International Congress every two years to highlight leading research activities in the clinical and basic research aspects of PDT.

About Ondine Biomedical Inc.

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with Research and Development laboratories in Bothell, Washington, USA and Minneapolis, Minnesota. Please visit the Company's website at: and For further information please contact us at: Ondine Biomedical Inc. info(at)ondinebio(dot)com.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Tissue Culture Biologicals, Inc. Hires James D. Titus to Lead New Expansion and Branding Development Effort
2. Ondine's CEO Carolyn Cross to be a Plenary Session Speaker at 14th World Congress of International Photodynamic Association
3. U.S. Congressman John Campbell Speaks at Southern California TechVoice Breakfast on May 10
4. Head to the Hill Advocacy Day Draws Hundreds to Capitol Hill to Speak-up for the Vital Needs of the Brain Tumor Community
5. BioConference Live Lands CMO of Roche Diagnostics and Other High Level Speakers
6. Selexis SA to Speak on Next Generation Innovations for Secretion Bottlenecks at the 2013 Protein Engineering Summit (PEGS)
7. uBiome CEO Jessica Richman Speaks at TEDMED, Launches Website
8. EtQ’s Chief Technology Officer to Speak at INTERPHEX
9. Entertainment Agency and Speaker Bureau Mark Sonder Productions Signs the Health & Wellness Shaman, Robert Cohen, PhD, LPC, DCEP for Meetings and Events Worldwide
10. Dyadic International To Speak At Advanced Biofuels Leadership Conference Panel Discussion
11. Slone Partners CEO & President Speak about Hiring Challenges in Molecular Diagnostics at Executive War College 2013
Post Your Comments:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
(Date:6/23/2016)... ... 2016 , ... UAS LifeSciences, one of the leading manufacturers ... Probiotics, into Target stores nationwide. The company, which has been manufacturing high quality ... list of well-respected retailers. This list includes such fine stores as Whole Foods, ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology:
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
(Date:5/12/2016)... May 12, 2016 , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):